Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
Recursion’s Pipeline Recursion’s internal pipeline as of Q2 2023 Deployed new digital chemistry technology, together…
Recursion’s Pipeline Recursion’s internal pipeline as of Q2 2023 Deployed new digital chemistry technology, together…
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., Aug. 08,…
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., Aug. 08,…
On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from…
On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from…
MALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”)…
MALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”)…
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating…
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating…
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense…
Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense…
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced…
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced…
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral…
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral…
Q2 Revenues of $28.8 million Q2 GAAP operating income $0.8 million, adjusted operating income $3.6…
Q2 Revenues of $28.8 million Q2 GAAP operating income $0.8 million, adjusted operating income $3.6…
Robust growth and efficient expense execution continues BOSTON and ROLLE, Switzerland, Aug. 08, 2023 (GLOBE…